Sort   by:  
 Page size 
GenomicsCharacterization of Early Gilteritinib Resistant Cell Lines
Characterization of Early Gilteritinib Resistant Cell Lines
PRJNA708339 | ENA
GenomicsBMX Kinase Mediates Gilteritinib Resistance in FLT3-mutated AML through Microenvironmental Factors
BMX Kinase Mediates Gilteritinib Resistance in FLT3-mutated AML through Microenvironmental Factors
PRJNA819410 | ENA
ProteomicsPhosphoproteomics of primary human FLT3-ITD+ AML cells treated with gilteritinib
Primary human AML cells (newly diagnosed, prior to treatment initation) were obtained from donor after consent and AML blasts were isolated by standard Ficoll centrifugation. AML blasts were treated with FLT3 inhibitor gilteritinib (or DMSO vehicle control) at 10 nM concentration for 6 h, followed b...
ORGANISM(S): Homo sapiens (Human) 
2022-08-25 | PXD034080 | Pride
Aml Gilteritinib Flt3 
GenomicsRNA-seq analysis of NRAS-mutant MV-4-11 AML cells treated with gilteritinib, clofarabine, or combined gilteritinib and clofarabine
RNA-seq analysis of NRAS-mutant MV-4-11 AML cells treated with gilteritinib, clofarabine, or combined gilteritinib and clofarabine
PRJNA1498160 | ENA
GenomicsMitoxantrone-liposome sensitizes Flt3-ITD acute myeloid leukemia to gilteritinib treatment
Mitoxantrone-liposome sensitizes Flt3-ITD acute myeloid leukemia to gilteritinib treatment
PRJNA1156893 | ENA
TranscriptomicsBMX Kinase Mediates Gilteritinib Resistance in FLT3-mutated AML through Microenvironmental Factors
While clinical benefit has been observed with gilteritinib, most patients relapse through unknown mechanisms. To investigate mechanisms of gilteritinib resistance, we performed targeted genomic sequencing and single cell (sc) RNASeq on primary FLT3-ITD-mutated AML samples. Co-occurring mutations in ...
ORGANISM(S): Homo sapiens 
2022-07-07 | GSE199333 | GEO
GenomicsAssessment of chromatin remodeling of acute myeloid leukemia cells treated with gilteritinib
Assessment of chromatin remodeling of acute myeloid leukemia cells treated with gilteritinib
PRJNA866495 | ENA
ProteomicsTranslatome proteomics of primary human FLT3-ITD+ AML cells treated with FLT3 inhibitors quizartinib, crenolanib, gilteritinib
Primary human AML cells (newly diagnosed, prior to treatment initation) was obtained from donor after consent and AML blasts were isolated by standard Ficoll centrifugation. Cells were treated ex vivo with DMSO vehicle control or 10 nM FLT3 inhibitors quizartinib, crenolanib, gilteritinib for 6 hour...
ORGANISM(S): Homo sapiens (Human) 
2022-08-25 | PXD034081 | Pride
Aml Gilteritinib Flt3 Translatome Quizartinib Crenolanib 
TranscriptomicsCharacterization of Early Gilteritinib Resistant Cell Lines
Expression analysis performed on Early Gilteritinib Resistant cell lines vs Acute (48hr) treatment and MOLM14 Parental
ORGANISM(S): Homo sapiens 
2021-05-19 | GSE168583 | GEO
GenomicsshCDK9 or shDHODH sensitizes cells to gilteritinib treatment by altering transcriptomes of AML cells
shCDK9 or shDHODH sensitizes cells to gilteritinib treatment by altering transcriptomes of AML cells
PRJNA769416 | ENA
Sort   by:  
 Page size